In a welcome move, Genmab ADR saw its Relative Strength Rating improve from 67 to 73 on Wednesday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks compares to the rest of the market.
History reveals that the best stocks typically have an 80 or higher RS Rating as they begin their largest runs. See if Genmab ADR can continue to rebound and hit that benchmark.
While it's not currently an ideal time to invest, see if the stock is able to form a consolidation and break out.
Earnings growth slowed in the most recent report from 0% to -71%. But revenue moved higher, from 19% to 31%.
The company earns the No. 96 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
